Corrigendum: Neurological adverse events associated with esketamine: A disproportionality analysis for signal detection leveraging the FDA adverse event reporting system

Схожие документы

• Corrigendum: Neurological adverse events associated with esketamine: A disproportionality analysis for signal detection leveraging the FDA adverse event reporting system
  по: Haoning Guo, и др.
  Опубликовано: (2022-11-01)
• A disproportionality analysis of FDA adverse event reporting system events for misoprostol
  по: Li Yang, и др.
  Опубликовано: (2025-01-01)
• Neurological adverse events associated with antidepressants: a comprehensive 22-year analysis of the FDA adverse event reporting system
  по: Qian Yu, и др.
  Опубликовано: (2025-08-01)
• Disproportionality analysis of post-marketing safety concerns associated with selumetinib in the FDA adverse event reporting system
  по: Fengfen Liu, и др.
  Опубликовано: (2025-03-01)
• Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database
  по: Chang-Zhu He, и др.
  Опубликовано: (2025-03-01)